INFLA HARMONY™: Tendons & Recovery

Assurance Maladie, France’s national health insurance body, defines tendonitis as “tendinopathy, also called tendonitis (inflammation caused by damage to a tendon).”

France’s National Authority for Health (HAS) details the mechanism for the most common form, at the elbow: “It is an overuse injury occurring following eccentric overload of the common tendon of the finger extensors and the extensor carpi radialis brevis, resulting from repetitive activities of the forearm and elbow.”

The term has changed because the damage observed is not always inflammatory. Assurance Maladie describes rotator cuff and long head of biceps tendinopathies as “degenerative tendon damage,” and adds a fact that often surprises people: “not all degenerative rotator cuff lesions cause pain, and they can remain silent.”

Sources (French institutions, quotes translated from French): Assurance Maladie, ameli.fr; HAS, scoping note validated by the Board on 8 January 2025. Accessed 22 August 2026.

Work, first. Assurance Maladie writes that “work is the main risk factor for epicondylitis” and cites tasks involving “gripping a handle (hammer, tool…) with forceful movements,” “simultaneous rotation of the forearm and flexion of the wrist,” “hand movements to strike objects.”

Sport comes next, in a smaller proportion than people imagine: “Playing tennis accounts for 5 to 10% of cases of epicondylitis.” Fencing, golf, rowing and baseball are also cited. At the shoulder, it is the cocking and throwing motions, “handball, volleyball, javelin, tennis.” At the heel, Achilles tendonitis “causes pain at the back of the heel, occurring at the start of physical effort or after intensive or repeated practice of certain sports (e.g. running).”

France’s National Authority for Health adds three individual factors: “tobacco use, obesity, or certain drug treatments (fluoroquinolone antibiotics).”

Sources (French institutions, quotes translated from French): Assurance Maladie, ameli.fr (epicondylitis, chronic shoulder pain, heel pain); HAS, scoping note of 8 January 2025. Accessed 22 August 2026.

It is explicitly listed among the aggravating factors. Assurance Maladie lists four things that “worsen tendon injuries”: “repetition of harmful movements,” “absence of rest or recovery time,” “working in the cold,” “exposure to vibration.”

On musculoskeletal disorders in general, it describes the same imbalance: they “result from an imbalance between the body’s physical capacities and the demands and strains it is exposed to,” and lists among organisational strains “insufficient recovery time.”

Source (French agency, quotes translated from French): Assurance Maladie, ameli.fr (epicondylitis, musculoskeletal disorders). Accessed 22 August 2026.

Both answers coexist, and they do not contradict each other: what needs to stop is the movement responsible, not movement in general.

On stopping, Assurance Maladie is clear: “Stopping the activities responsible for epicondylitis is necessary,” and treatment “mainly relies on resting the affected tendons.” For the heel, “heel pain caused by tendonitis may require stopping the physical activities that trigger the pain.”

On movement, it is equally clear: for the shoulder, “immobilising the shoulder is not advised,” and the doctor works with the patient to identify “which activities to continue without strongly triggering the pain.”

Sorting between the two calls for a clinical examination, not a web page.

Source (French agency, quotes translated from French): Assurance Maladie, ameli.fr (epicondylitis, chronic shoulder pain, heel pain). Accessed 22 August 2026.

A long time, and this is the least pleasant answer on this page. For epicondylitis, Assurance Maladie states that “spontaneous recovery takes a long time, between 9 and 24 months, averaging 12 months,” and that “early treatment speeds up recovery.” It notes elsewhere that “recovery happens spontaneously, on average within 12 months of symptom onset.”

You will find no timeframe stated on this page. No one is in a position to state one.

Source (French agency, quote translated from French): Assurance Maladie, ameli.fr. Accessed 22 August 2026.

A central one. France’s National Authority for Health writes that “rehabilitation is considered essential for relieving pain.” In the same document, it notes that “83% to 90% of people with lateral elbow tendinopathies are managed with passive rehabilitation, associated with a recurrence rate of one third beyond one year,” while some recommend “active treatments, based on exercise and requiring the patient’s constant, ongoing commitment.”

For the shoulder, Assurance Maladie describes physiotherapy that “can be enough to relieve the patient within a few weeks,” and notes that “the patient’s cooperation is necessary.”

Sources (French institutions, quotes translated from French): HAS, scoping note of 8 January 2025; Assurance Maladie, ameli.fr. Accessed 22 August 2026.

Less than people think. A Cochrane review published on 27 May 2025 on patellar tendinopathy pooled seven trials and 211 participants, all athletes. Its conclusion is cautious: “We are very uncertain whether strengthening exercise reduces pain compared to no treatment,” and the exercises “may make little or no difference to function compared to no treatment.”

The authors also note they found no trial comparing exercise to a placebo (“We did not find any studies that compared exercise with placebo or sham intervention”), and explicitly limit their conclusions to athletes.

This does not mean exercise is useless. It means the evidence, for this location, is weak. That is the kind of nuance we prefer to state.

Source: Lopes AD, Rizzo RRN, Hespanhol L, Costa LOP, Kamper SJ, “Exercise for patellar tendinopathy,” Cochrane Database of Systematic Reviews 2025, Issue 5, CD013078.pub2. Accessed 22 August 2026.

Yes, under certain conditions. Assurance Maladie refers to “table 57 A of occupational illnesses under the general scheme” for chronic shoulder pain and “table 57 B” for epicondylitis, and notes that “requests for recognition must be sent by the insured person to their health insurance fund.”

The scale of the issue: “in France, musculoskeletal disorders (MSDs) increased by 6.7% between 2023 and 2024 and account for 90% of occupational illnesses.” France’s National Authority for Health cites a 2002 study putting, for lateral elbow epicondylitis, “an average cost of €18,220 and average sick leave of 195 days.”

Sources (French institutions, quotes translated from French): Assurance Maladie, ameli.fr; HAS, scoping note of 8 January 2025. Accessed 22 August 2026.

No, and this is not a note of caution. ANSES, France’s food safety agency, states it as a definition: “A food supplement is not a medicine, and can therefore not, by definition, claim any therapeutic effect.”

A food supplement therefore replaces neither a diagnosis, nor a treatment, nor the advice of a doctor, physiotherapist or pharmacist. And if pain persists, Assurance Maladie is clear on what to do: “If elbow pain persists for several days, it is important to arrange a medical consultation.”

Sources (French agencies, quotes translated from French): ANSES, “Food supplements: the need for informed consumption,” 21 March 2025; Assurance Maladie, ameli.fr. Accessed 22 August 2026.

No. Neither France’s National Authority for Health in its January 2025 scoping note, nor Assurance Maladie in its pages on epicondylitis and chronic shoulder pain, lists a food supplement among the treatments described. What does appear: resting the tendons, correcting movements and posture, painkillers, corticosteroid injections, physiotherapy and, as a last resort, surgery.

France’s National Authority for Health also notes, regarding this whole set of treatments: “To date, many medical treatments exist, none of which has clearly demonstrated superiority.”

We sell a food supplement, not a treatment. This is precisely why this page talks about composition, not results.

Sources (French institutions, quotes translated from French): HAS, scoping note of 8 January 2025; Assurance Maladie, ameli.fr. Accessed 22 August 2026.

Yes, and stating this here seems more useful than leaving it out. On 17 July 2024, ANSES published a warning with figures: “Between 2016 and February 2024, 154 new cases of adverse effects were reported following consumption of these products, 18 of which were considered very serious. Two deaths occurred and four people had their life put at risk.”

These reports mainly concern products consumed “to build muscle mass or reduce fat mass,” which is not the category this formula belongs to. The Agency’s recommendations nonetheless apply to everyone: “avoid consuming several food supplements or fortified foods at the same time, or combining them with medicines,” and “before consuming them, seek the advice of a health professional, doctor or sports dietitian.”

Source (French agency, quote translated from French): ANSES, news release of 17 July 2024, “Food supplements and fortified foods for athletes: risky consumption patterns.” Accessed 22 August 2026.

This question needs asking before purchase, not after. ANSES notes that “even where it meets regulatory requirements, an ingredient may not be authorised by the World Anti-Doping Agency (WADA),” and advises athletes to “pay close attention to the composition of the products they consume, favouring in particular products compliant with the European standard EN17444:2021.”

We do not claim this certification for this formula. Its full composition is, however, published in the Ingredients tab on this page, active by active, with amounts and standardisation. If you are subject to testing, have this list checked by your sports doctor or federation before taking it.

Source (French agency, quote translated from French): ANSES, news release of 17 July 2024. Accessed 22 August 2026.

ANSES sums up its profile in one sentence: “The pharmacokinetic profile of curcumin shows very low oral absorption, rapid metabolism and elimination.”

The figures are telling. In a study conducted in humans with single doses of 500 to 12,000 mg, the Agency reports that “curcumin is undetectable in serum for administered doses of 500 to 8,000 mg.” On elimination: “Numerous studies in rats have shown that most curcumin is found in stools after oral ingestion, while a tiny amount is found in urine.”

ANSES lists the techniques used to address this: “the addition of adjuvants such as piperine, the inclusion of curcumin in a lipophilic matrix, encapsulation with surfactants, or the administration of structural analogues.” The form used in this formula follows the second of these routes.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2019-SA-0111. Accessed 22 August 2026.

Yes, and it would be dishonest not to state this on the page of a product that contains it.

The French and Italian vigilance schemes “have recorded more than 40 cases of hepatitis occurring between 2002 and 2021 during the consumption of food supplements containing turmeric or curcumin, for which causality is considered likely or very likely in 9 cases.” ANSES “advises against the consumption of turmeric by people suffering from disorders of the biliary tract” and considers that this consumption “should be avoided in people treated with anticancer medicines or medicines with a narrow therapeutic margin, such as anticoagulants.”

On amounts, the Agency considers that “taking such supplements raises no particular concern as long as consumption does not exceed an intake of 153 mg of curcumin per day for a 60 kg adult.” It attaches a caveat that concerns us directly: “the ADI set by EFSA does not apply to formulations in which the bioavailability of curcumin has been increased.” This formula provides 92 mg of curcuminoids per daily dose and uses an encapsulated form: one more reason to follow the stated dose and seek medical advice if you are on ongoing treatment.

The full precautions for use appear in the dedicated tab on this page.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2019-SA-0111. Accessed 22 August 2026.

A standardised, or titrated, extract is an extract whose content of a given compound is measured and stated, and stays constant from one batch to the next.

The gap with plant powder is considerable. According to ANSES, curcuminoids are present in Curcuma longa rhizomes at concentrations that are “highly variable depending on geographic origin, soil composition and growing conditions,” “generally between 0.3 and 5.4% (w/w, dry weight),” while the purification process “yields an orange-yellow crystalline powder containing more than 95% curcuminoids.”

Standardisation is not just a matter of vocabulary: in a fraud-control survey reported by ANSES, “in four samples, the curcuminoid content was lower than stated,” and “in one sample, the presence of piperine was identified even though the label made no mention of it.”

One honest clarification to finish: a standardisation states a content. It says nothing about absorption, and nothing about efficacy. These are three separate questions.

Source (French agency, quotes translated from French): ANSES, opinion on referral No. 2019-SA-0111. Accessed 22 August 2026.

Because European Regulation 1924/2006 governs health claims, and those relating to botanical substances have never been settled.

EFSA already documented this in its statement of 28 July 2011: of the 4,637 claims transmitted between July 2008 and March 2010, “1,548 claims on ‘botanicals’ have been placed on hold by the Commission pending further consideration on how to proceed with these.”

Fifteen years on, nothing has changed. The Court of Justice of the European Union confirmed this in its ruling of 30 April 2025: “the assessment of health claims relating to botanical substances has been suspended and the list concerning such claims has not yet been drawn up.”

A brand that makes a claim regardless is no better informed than anyone else. It is simply less cautious.

Sources: EFSA, statement of 28 July 2011; CJEU, ruling of 30 April 2025, case C-386/23, Novel Nutriology, paragraph 55. Accessed 22 August 2026.

One nuance exists, however, and we apply it. Among the claims still pending are statements relating to joint health, usable under the transitional regime provided for in Article 28 of the Regulation. On this basis, and this basis only, this page states that turmeric and boswellia contribute to joint health. No statement referring to a disease is possible, and you will find none here.

It is not recommended in cases of biliary obstruction or biliary function disorders, for pregnant or breastfeeding women, for people with diabetes, or when taking anticoagulants, anticancer medicines or immunosuppressants.

Do not exceed the recommended daily dose. This product is not a substitute for a healthy lifestyle or a varied, balanced diet. Keep out of reach of young children.

If you are on ongoing treatment, seek the advice of a doctor or pharmacist.

The pages in this range describe the same product: the same actives, the same amounts, the same 120-capsule bottle, the same dose of four capsules a day. What changes from page to page is not the formula, it is the context in which you arrived here, and the detail we take the time to give you.

This page is written for readers who train, or whose job relies on repeated movements. If your situation is different, the same composition is presented elsewhere from a different angle: if you are over fifty, if your episodes keep coming back, if your job is spent at a desk, if you want to compare labels first, or the chronic pain supplement page when the subject has gone on for a long time. Same public sources, same list of actives.

Whichever page you choose, the full composition is identical and published in the Ingredients tab on this page. Single purchase, pack of 2, pack of 3, or a monthly subscription at €29.90 instead of €39.90, cancellable at any time.

On the topic of joints, European regulation authorises one statement under the pending claims: boswellia contributes to the health of joints and bones. This formula provides 307 mg per daily dose, as a concentrated extract standardised to 65% boswellic acids, providing 200 mg of boswellic acids.

Beyond this sentence, nothing more can be stated, by us or by anyone else.

The same framework applies: turmeric contributes to joint health. This formula provides 400 mg of Longvida® curcumin, including 92 mg of curcuminoids, extracted using the patented “Solid Lipid Curcumin Particle” technology.

As ordinary curcumin is very poorly absorbed, it was the form that guided this choice, not the raw quantity. Here again, nothing else can be stated.